Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type* A' W! m4 @% k) J0 u+ s* v
NOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9
7 S- B% w% F) _& {% M+ Author Affiliations: H2 b% \# q1 M. k, _$ A4 ?3 m
* f+ [8 }: n/ j1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan
1 B6 V$ [0 J. S3 a0 D( ^2 x: M2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan ! b+ o! A. Q- H
3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
+ F- x/ J5 d \( D1 B+ k% J4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan
$ n% m# g7 f2 O! A5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan
5 B" @, ^- [) F( T; U. C6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan
0 s; x$ j, F! g0 }" [2 n$ B7Kinki University School of Medicine, Osaka 589-8511, Japan
! s8 S& ] M1 ^9 \: p( M8Izumi Municipal Hospital, Osaka 594-0071, Japan
7 `0 ~5 K' A' i3 f9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan 9 L: R/ `' Z* v2 ~. ^6 [
Correspondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp ! o3 Q, M4 F r! {+ J9 p+ U. `
AbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type.
1 z; S6 @. |" H8 g3 }9 v9 P6 |# c+ E+ `' b3 {
|